Rhinitis

The purpose is to learn whether the over-the-counter amino acid supplement 5-hydroxytryptophan 5HTP, isolated from the plant Griffonia Simplifolia, can reduce allergic lung responses, improve lung function, and reduce anxiety and depression symptoms in children with allergic asthma. Participants will be randomly assigned to receive either 5HTP or a placebo and will later crossover to the other group. There are 5 study visits over about 12 weeks. The primary outcome is the change in FEV1. The investigators anticipate that 5HTP at the proposed doses will improve lung function as seen in preclinical studies using clinically relevant 5HTP. Other outcomes include blood eosinophil counts, eosinophil numbers in nasal fluid, lung inflammation, and changes in anxiety and depression scores measured using CES-DC and SCARED questionnaires. The study also examines whether 5HTP increases cortisol and prolactin without altering systemic plasma concentrations of 5HTP, serotonin, 5-hydroxyindoleacetic acid 5-HIAA, and dopamine. The results have the potential to influence approaches to improve lung function and asthma-associated anxiety and depression.

Researchers are evaluating the safety and effectiveness of SHR-1819 injection in treating adults with seasonal allergic rhinitis, a condition causing nasal allergy symptoms during pollen seasons. This phase II study is randomized, double-blind, and placebo-controlled, aiming to understand how the drug affects nasal symptoms and its behavior in the body. Participants are randomly assigned to receive one of two doses of SHR-1819 injection or a placebo. The study includes a treatment period lasting up to 4 weeks, where the impact on nasal symptoms is closely monitored. The trial also tracks safety by recording any adverse events for up to 12 weeks. Throughout the study, participants will complete daily symptom diaries and undergo assessments to measure changes in nasal symptoms using a total nasal symptom score. Researchers will collect data on how the drug is processed in the body and monitor participants safety. The total participation time may extend beyond the treatment period to capture all necessary outcome and safety information.

This research observes children who took part in the TEMPO clinical trial during their first year of life to understand if their early feeding patterns affect the development of allergies or infections in childhood. The study follows these children up to 7.5 years to gather information on allergic symptoms, infections, and related medical care. It is an observational study without additional treatments or interventions. Participants complete self-administered digital questionnaires every three months using a smartphone, tablet, or computer. These questionnaires collect data on allergies, infections, medication use, medical device use, hospitalizations, and emergency room visits. The study is entirely virtual and decentralized, allowing families to participate remotely. Throughout the study, parents provide information via regular online questionnaires, helping researchers track their childs health over time. The main measurements include parent-reported symptoms, medication or device use, and healthcare visits related to allergies and infections. The study runs until March 2029 and includes children aged 3 to 10 years who completed the original TEMPO study.

This research aims to develop and test a modified minimally invasive surgical technique for sinus floor augmentation in patients with a residual bone height of 3 to 6 millimeters. The goal is to create a reliable implant bed of at least 10 millimeters in height after a healing period of 3 to 5 months. The study also seeks to reduce patient stress compared to traditional methods. Participants will undergo the sinus floor elevation procedure, which is being evaluated to improve outcomes and comfort. This surgical technique is studied on a pilot group of 12 patients, with no placebo or comparative treatments involved. The procedure targets the maxillary sinus area to enhance bone structure for dental implant placement. During the study, participants will be monitored to measure the height of bone augmentation after 4 to 5 months of healing. The research team will assess the surgical results and patient recovery, including any side effects or complications. The total duration includes the surgery followed by the healing and evaluation period to determine the procedures effectiveness and patient impact.

Researchers are evaluating the efficacy and safety of Antiwei granules for treating the common cold, specifically the wind-cold syndrome. This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial sponsored by Tasly Pharmaceutical Group Co., Ltd. It aims to assess how well Antiwei granules work and how safe they are in adults aged 18 to 65 with recent onset of common cold symptoms. Participants will be randomly assigned to receive either Antiwei granules or a matching placebo. The treatment involves taking one sachet of granules 6 grams orally three times a day, for three days. Both groups follow the same dosing schedule, taking nine sachets total. The study compares outcomes between the Antiwei granule group and the placebo group over this short treatment period. Throughout the trial, participants will be closely monitored with assessments focusing on the cure rate after three days of treatment. Researchers will also track symptom recovery time, remission rate, disappearance of individual symptoms, traditional Chinese medicine syndrome efficacy, changes in symptom severity, occurrence of complications, emergency medication use, and overall cure of cough and cold symptoms. The total participation time includes the three-day treatment and monitoring period to evaluate treatment effects and safety.

Seasonal Allergic Rhinitis SAR is an inflammatory condition caused by an immune system reaction to allergens such as grass and birch pollen. It affects millions worldwide and causes bothersome nasal symptoms for weeks during allergy seasons. This trial studies acupuncture targeting the sphenopalatine ganglion SPG, a nerve cluster near the nasal area, to see if it can better relieve SAR symptoms compared to sham acupuncture or medication alone. The study is randomized and aims to provide evidence on acupunctures safety and effectiveness for SAR. Participants will be randomly assigned to one of three groups an acupuncture group receiving needles inserted near the SPG to stimulate the nerve, a placebo acupuncture group receiving shallow needle insertion without stimulation, or a rescue medication group receiving no acupuncture but allowed to use medication if needed. Acupuncture sessions involve specific needle placement and stimulation lasting about 30 minutes. The rescue medication group may choose to receive acupuncture after the study period. During the study, participants allergy symptoms and medication use will be tracked daily for up to eight weeks, with additional follow-up during the next allergy season. Researchers will assess changes in combined symptom and medication scores, quality of life, and global improvements. Participants will complete symptom questionnaires and medication diaries, and their safety will be monitored throughout the trial lasting until the end of 2026.

This research aims to understand how co-existing health conditions, medical history, and allergy tests affect the results of allergen provocation tests in children. The study includes children from birth up to 18 years old who are being investigated for allergies to foods or antibiotics. It is a prospective observational study conducted at the Hans Christian Andersen Childrens Hospital. Participants undergo oral provocation tests where small, increasing amounts of allergens are given to assess allergic reactions. The allergens studied include antibiotics and a variety of common food allergens such as milk, egg, peanut, hazelnut, sesame, wheat, various nuts, soy, fish, shellfish, and poppy seed. Each child is assigned to a group based on the specific allergen they are being tested for. During the study, data on demographics, co-existing conditions, symptoms, skin prick tests, specific IgE levels, and details from the provocation tests are collected and entered into a database. Researchers will assess the relationship between allergy test results and provocation outcomes over a five-year period. Children will be monitored through these evaluations to better understand allergy responses and test effectiveness.

Researchers are investigating early warning signs and biomarkers for dementia with Lewy bodies DLB, a common cause of dementia linked to the buildup of misfolded alpha-synuclein protein in the brain. The study focuses on people with idiopathic olfactory dysfunctionloss or reduction of smell without known causeto better understand symptom progression and improve early diagnosis, potentially aiding future treatments. Participants include people with and without olfactory dysfunction. The study uses Real-Time Quaking-Induced Conversion RT-QuIC, a laboratory technique that detects misfolded alpha-synuclein, to assess samples from participants. It involves an exploratory cross-sectional case-control design and a long-term follow-up using Danish health registries to track diagnoses of Parkinsons disease or dementia. During the study, participants undergo smell tests, motor function exams, cognitive assessments, and evaluations of other symptoms related to Parkinsons disease and DLB at regular intervals over 24 months and longer. Researchers monitor the presence of misfolded alpha-synuclein and track diagnoses over up to 8 years. This observational study helps identify early signs and disease progression markers while participants continue their usual care.

Researchers are evaluating the use of an artificial intelligence AI app to improve the diagnosis and treatment of ear infections in young children aged 6 to 24 months who have cold symptoms. Ear infections can be hard to diagnose accurately in this age group due to small ear canals and limited examination time. The study aims to see how the AI app affects clinical decisions about ear infections and antibiotic use compared to standard clinical exams. The study involves 300 children who will have their ears examined both with the AI app using a smartphone-attached otoscope and by a clinician using a standard otoscope. Each child will receive two ear exams during a single visit. The AI app records and analyzes images to provide a diagnosis and treatment recommendation, which is compared to the clinicians diagnosis. Clinicians will then review the AI apps findings before making a final treatment decision. The study uses a within-subject design where each childs ears are assessed by both methods to compare antimicrobial prescription rates and diagnosis accuracy. Participants will be monitored for 10 days after enrollment to track symptom changes and any side effects from antibiotic use, such as diarrhea or diaper rash. Parents will enter daily symptom scores in electronic diaries. Medical records will be reviewed for three months to identify any recurrences of ear infections. The primary outcome is the rate of antimicrobial prescriptions on the day of diagnosis. Secondary outcomes include diagnostic rates, image quality, symptom severity scores, and infection recurrences. The total study participation involves one visit for exams and follow-up symptom tracking and record review.

Researchers are evaluating four different isotonic and hypertonic seawater-based nasal sprays in real-life settings for their effectiveness, safety, usage, tolerance, and user satisfaction. The study focuses on infants, children, adults, and pregnant or breastfeeding women who have acute or chronic sinonasal conditions such as upper respiratory tract infections, allergic rhinitis, chronic rhinosinusitis, bronchiolitis, COVID-19, and post-surgery nasal issues. The investigation aims to understand how these devices perform when used as intended across various patient groups. Participants will use one of four CE-marked nasal spray devices according to their specific indications and target populations. The sprays include Respimer Hygiene-Prevention for babies, kids, and adults, Respimer Decongestion for babies from two months old and older, and Phytosun arms Hypertonic nasal wash for children six years and older and adults. Usage instructions vary by product, ranging from 1 to 6 sprays per nostril daily, with different frequencies for treatment and prevention purposes. The study period covers up to three months to assess both short-term and longer-term effects. During the study, participants or their parents will complete online questionnaires and follow healthcare providers advice on nasal wash techniques. Researchers will monitor nasal symptom changes, including intensity and frequency, improvement in nasal breathing, quality of life, and satisfaction with the sprays. Effectiveness will be evaluated from day 0 to day 5 for acute conditions and up to day 14 for chronic issues, extending to three months for seasonal symptom management. Safety, tolerance, and usage patterns will also be recorded throughout the study.